Efficacy of Adapted Physical Activity on a Walking Platform in Elderly Patients HOspitalized for Cancer Surgery

Launched by CENTRE FRANCOIS BACLESSE · Jan 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how using a walking platform every day can help older patients recover better after cancer surgery. Specifically, it looks at whether this daily activity can improve how fast patients can walk when they leave the hospital. The trial is open to men and women aged 65 and older who are scheduled for major cancer surgery and are able to walk for at least 10 minutes on the walking platform during an initial test.

To participate, patients must be generally healthy enough to walk and be able to give informed consent. However, those with certain health issues, like severe weight loss or emergency surgeries, cannot join. If eligible, participants can expect to use the walking platform daily during their hospital stay, which may help speed up their recovery and improve their walking ability by the time they go home. This trial is currently recruiting participants, and it aims to provide valuable insights into the recovery process for elderly cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men or women aged 65 or over
• • Candidate for scheduled major oncological surgery and/or surgery with high morbidity
• • Patient able to walk for 10 minutes on the walking platform at the time of the test
• • Patient affiliated to a social security system
• • Signature of informed consent prior to any specific study-related procedure
• Exclusion Criteria:
• • Patient with severe undernutrition (BMI\<18, and/or weight loss \>15% in 6 months or \>10% in 1 month)
• • Emergency surgery
• • Physical contraindications preventing use of the platform
• • Simultaneous participation in another clinical study that could compromise the conduct of this study
• • Patients deprived of their liberty, under guardianship or subject to a legal protection measure, or unable to express their consent.
• • Patient unable to undergo trial follow-up for geographical, social or psychopathological reasons.